Citi initiated coverage of Roivant Sciences (ROIV) with a Buy rating and $16 price target The firm also added an “upside 90-day catalyst watch” on the shares. Citi sees favorable risk/reward for Roivant shares into the brepocitinib Phase 3 data in dermatomyositis. The firm expects the data in September.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Positive Outlook for Roivant Sciences Driven by Brepocitinib’s Phase 3 Potential and Undervalued Stock
- 3 Stocks to Buy Now, According to the Technical Analysis
- Roivant Sciences Earnings Call: Progress Amid Challenges
- Promising Potential of Roivant Sciences’ Brepocitinib and Pipeline Fuels Buy Rating
- Roivant Sciences Reports Q1 2025 Financial Results